Speaker Credentials
MS-II
Speaker Credentials
BS
College
College of Allopathic Medicine
Medical Specialty
Internal Medicine
Format
Poster
Start Date
November 2024
End Date
November 2024
Track
3
Abstract
Objective. This study was conducted to assess the real-world safety and efficacy of elranatamab in patients with relapsed or refractory multiple myeloma (RRMM). Background. Multiple myeloma is a hematological malignancy marked by uncontrolled proliferation of clonal plasma cells. Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In August 2023, the FDA granted elranatamab accelerated approval for the treatment of patients with RRMM based on positive results from the Phase II MagnetisMM-3 clinical trial. However, the drug’s real-world safety and efficacy have yet to be established. Methods. This retrospective chart review conducted at Moffitt Cancer Center evaluated 34 patients with RRMM receiving standard-of-care elranatamab between September 2023 and July 2024. Responses were graded in accordance with IMWG response criteria, while treatment-related toxicities—cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS)—were graded using ASTCT consensus criteria. Results. The overall response rate (ORR) was 52.9%, with 32.4% and 14.7% of patients displaying evidence of CRS and ICANS, respectively. Conclusion. This study’s results are comparable to those from the MagnetisMM-3 trial. Notably, the patients in this real-world study demonstrated a satisfactory ORR and safety profile despite a larger proportion of them having poor prognostic indicators, including inferior ECOG performance status, high-risk cytogenetics, and many prior lines of therapy. These findings support the continued development of elranatamab as monotherapy, as well as further investigation of its performance in combination with other anti myeloma agents. Grants. No external funding was received for this research.
Included in
Real-World Safety and Efficacy of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
Objective. This study was conducted to assess the real-world safety and efficacy of elranatamab in patients with relapsed or refractory multiple myeloma (RRMM). Background. Multiple myeloma is a hematological malignancy marked by uncontrolled proliferation of clonal plasma cells. Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In August 2023, the FDA granted elranatamab accelerated approval for the treatment of patients with RRMM based on positive results from the Phase II MagnetisMM-3 clinical trial. However, the drug’s real-world safety and efficacy have yet to be established. Methods. This retrospective chart review conducted at Moffitt Cancer Center evaluated 34 patients with RRMM receiving standard-of-care elranatamab between September 2023 and July 2024. Responses were graded in accordance with IMWG response criteria, while treatment-related toxicities—cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS)—were graded using ASTCT consensus criteria. Results. The overall response rate (ORR) was 52.9%, with 32.4% and 14.7% of patients displaying evidence of CRS and ICANS, respectively. Conclusion. This study’s results are comparable to those from the MagnetisMM-3 trial. Notably, the patients in this real-world study demonstrated a satisfactory ORR and safety profile despite a larger proportion of them having poor prognostic indicators, including inferior ECOG performance status, high-risk cytogenetics, and many prior lines of therapy. These findings support the continued development of elranatamab as monotherapy, as well as further investigation of its performance in combination with other anti myeloma agents. Grants. No external funding was received for this research.